Pancreatic cancer is among the top five deadliest cancers in developed countries. Better knowledge of the molecular mechanisms contributing to its tumorigenesis is imperative to improve patient prognosis. Identification of novel tumor suppressor genes (TSGs) in pancreatic cancer will reveal new mechanisms of pathway deregulation and will ultimately help improve our understanding of this aggressive disease. According to Knudson's two-hit model, TSGs are classically disrupted by two concerted genetic events. In this study, we combined DNA methylation profiling with copy number and mRNA expression profiling to identify novel TSGs in a set of 20 pancreatic cancer cell lines. These data sets were integrated for each of B12 000 genes in each cell line enabling the elucidation of those genes that undergo DNA hypermethylation, copy-number loss and mRNA downregulation simultaneously in multiple cell lines. Using this integrative genomics strategy, we identified SOX15 (sex determining region Y-box 15) as a candidate TSG in pancreatic cancer. Expression of SOX15 in pancreatic cancer cell lines with undetectable expression resulted in reduced viability of cancer cells both in vitro and in vivo demonstrating its tumor suppressive capability. We also found reduced expression, homozygous deletion and aberrant DNA methylation of SOX15 in clinical pancreatic tumor data sets. Furthermore, we deduced a novel role for SOX15 in suppressing the Wnt/b-catenin signaling pathway, which we hypothesize is a pathway through which SOX15 may exert its tumor suppressive effects in pancreatic cancer.
INTRODUCTION
Pancreatic cancer has a very poor prognosis, making it one of the top five most lethal malignancies in developed countries. 1 Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent form, comprising up to 90% of cases, and is characterized by mutations to key oncogenes and tumor suppressors (TSGs) including KRAS, EGFR, TP53, SMAD4 and CDKN2A. [2] [3] [4] Tumor heterogeneity is a prominent feature of pancreatic malignancies and represents a major challenge in studying PDAC. 5 In addition to intratumoral, histological and genetic differences, the majority of tumors typically exhibit marked desmoplasia, characterized by infiltration of nonmalignant cells such as fibroblasts and inflammatory cells, which commonly mask the identification of genetic alterations. 2, 3 For this reason, cell lines and xenografts enriched for tumor cells have become essential tools in PDAC research.
Despite the recent elucidation of some key driver genes and core signaling pathways, much remains to be learned about the biology driving PDAC tumorigenesis. [6] [7] [8] [9] [10] [11] [12] A better understanding of the molecular mechanisms underlying PDAC biology, including the discovery of new TSGs, is imperative for improving patient outcome. Inactivation of TSGs can occur through several different mechanisms such as mutation and loss of heterozygosity. DNA methylation and deletions are also prominent mechanisms of TSG silencing in cancer. Thus, consideration of multiple genomic dimensions simultaneously is a powerful approach for TSG identification as it facilitates detection of genes with 'two-hit' inactivation achieved through different molecular mechanisms. 13 In this study we performed DNA-methylation profiling in conjunction with copy number and gene expression profiling to identify novel TSGs in PDAC. Our integrative, multi-omics approach resulted in the discovery of the candidate TSG, SOX15 (sex determining region Y-box 15), a member of the SOX gene family, which encodes 20 proteins harboring high-mobility group box domains that act as transcriptional activators or repressors, and function in development and cell differentiation. 14 Additionally, we are the first to show that SOX15 represses Wnt b-catenin signaling.
RESULTS

Screen for hypermethylated and underexpressed genes in PDAC
We first screened a panel of 20-cell lines representing the spectrum of PDAC to identify recurrently hypermethylated genes. Clinical and molecular features of these cell lines are summarized in Table 1 . To identify the most robust candidates, we calculated delta b-values (percent difference in methylation) for all CpG sites in each line with reference to normal human pancreatic duct epithelial (HPDE) cells, and used a stringent threshold of delta b-values in the 95th percentile for defining hypermethylation. This corresponded to a 53% difference in methylation between PDAC lines and HPDE. In total, 1752 CpG probes corresponding to 1310 unique genes were identified as hypermethylated in 30% of PDAC lines (Supplementary Table 1 ). We used a stringent frequency threshold as recurrence suggests biological relevance. A number of these genes have recently been reported as hypermethylated in PDAC, demonstrating the validity of our approach.
If biologically relevant, gene hypermethylation should result in downregulation of gene expression. Thus, to prioritize our list of hypermethylated genes to those most likely to have an effect on PDAC biology, we looked for those with a minimum two-fold decrease in expression relative to HPDE within individual cell lines. Using this criterion, we identified 247 genes with concurrent hypermethylation and underexpression in at least 30% of PDAC lines (Figure 1a, Supplementary Table 2 ). Among these genes were a number of known and candidate TSGs including SFRP1, SOX17, TUSC3, CDH13 and TIMP3.
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Two-hit genes: concurrent hypermethylation, DNA copy-number loss and underexpression Integration of DNA methylation, copy number and mRNA expression profiles for individual genes within individual cancer lines allowed us to screen our list of hypermethylated genes for those which also harbored copy-number loss. As our strategy is based on the two-hit model, we hypothesized DNA deletions would complement hypermethylation, providing a second hit for gene inactivation. Array CGH data were segmented to determine the copy number status (gain, loss or neutral) for each gene in each PDAC genome. Copy number alterations are summarized in Supplementary Tables 3 and 4 . Of our 247 hypermethylated genes, 185 exhibited concurrent copy-number loss in at least one sample.
Inactivation of genes by two-hit events is a rare occurrence that implies selection against important genes, and likely leads to gene silencing and a growth advantage for cancer cells. As recurrence of the two-hit phenomenon in multiple samples would provide even further evidence of selection against a gene in PDAC, we implemented an arbitrary but stringent two-hit frequency threshold of 15% for candidate genes to move forward in our analysis ( Figure 1a ). This recurrence threshold revealed 91 two-hit genes based on our integrative genomic analysis (Supplementary Table 5 ).
Two-hits at specific gene candidates occur remarkably more often than expected by chance To determine if the two-hit genes were identified by chance, we performed a calculation based on our observed frequencies of methylation, copy number and expression changes. For each cell line, we calculated the number of genes with hypermethylation, copy-number loss and underexpression, and calculated the average proportion of genes (of 11 984 genes assessed) affected by each of these alterations across the 20 PDAC lines. Given that our definition of two-hits required all three of these events to occur simultaneously, we multiplied the average proportions for each event to calculate the proportion of genes expected to undergo two-hits by chance. The average proportions for each event were: hypermethylation 0.0547, copy-number loss 0.2064 and underexpression 0.2601. Thus, the average probability of a gene being affected by two-hits in a single cell line was 0.0029. Furthermore, the probability of observing two-hits in a single gene in three of 20 lines (15% of samples) drops to 2.4 Â 10 À 8 , a probability so low that we would not expect to identify any genes by chance (11 984 genes Â 2.4 Â 10 À 8 ¼ 0.0003 genes).
Clinical relevance of gene expression changes As a final means to refine our list of two-hit genes, we examined expression in clinical pancreatic tumors compared to nonmalignant pancreatic tissues ( Figure 1a ). As cell lines have adapted to artificial in vitro conditions, assessing candidate gene expression in actual tumor samples is essential to rule out artefacts of tissue culture. Expression data for the 91 candidates was extracted from two independent clinical data sets from the Gene Expression Omnibus data repository (GSE11838: 28 tumors and 4 normals, and GSE15471: 36-matched tumors and normals, see Methods). A total of 24 genes were differentially expressed (U test P-valueo0.05), having significantly lower expression in pancreatic tumors versus non-malignant pancreas tissues, consistent with gene downregulation (Table 2) .
Over-representation of two-hit genes in the Wnt/b-catenin pathway Upon refining our list of two-hit genes, we sought to understand how they might contribute to PDAC biology. We used pathway analysis to uncover biological relationships between these genes in order to discern the cellular pathways deregulated as a consequence of their disruption. This analysis revealed that the Wnt/b-catenin pathway was significantly enriched for two-hit inactivation of pathway inhibitors, including SFRP1 and DKK2. In fact, the Wnt/b-catenin pathway was the only significantly enriched pathway we observed (Benjamini Hochberg corrected Fisher's exact test P-value ¼ 0.005, Figure 1b , Supplementary  Figure 1 ). Two-hit inactivation of known pathway inhibitors is Four of our twenty-four two-hit genes were identified as being involved in Wnt signaling, all with inhibitory roles, and two-hit inactivation of at least one of the four genes occurred in 12 of the 20 cell lines (60%) (Figure 1c) . SFRP1, DKK2 and WNT7A act upstream in the pathway at the level of receptor-ligand binding, whereas SOX15 is predicted to act downstream at the level of transcription (Supplementary Figure 1) . To our knowledge, this is the first report to describe two-hit inactivation of the Wnt suppressors SFRP1 and DKK2 in cancer, as silencing of these TSGs is predominantly described as occurring through aberrant DNA methylation. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Identification of SOX15 as a novel candidate TSG Whereas SOX family members, such as SOX17 and SOX6, are established TSGs in other cancer types, SOX15 has not previously been described as a TSG. 18, 20, 38, 39 We proceeded to investigate the role of SOX15 as a novel TSG in PDAC, because (1) we observed strong genomic evidence of its inactivation, (2) other SOX members function as Wnt antagonists, (3) the three other Wnt pathway genes (SFRP1, DKK2 and WNT7A) we identified have already been shown to be TSGs and (4) SOX15 has never been described as a TSG before.
We observed two-hits affecting SOX15 in 9 of 20 (45%) PDAC lines ( Table 2 ). Of the 24 candidate genes identified, SOX15 had the second highest two-hit frequency (45%), second only to SERPINB13 that showed two-hits in 10 of 20 (50%). However, SERPINB13 transcript levels were underexpressed in 70% of the cell lines, whereas SOX15 was underexpressed in 100%, providing further rationale for investigation of SOX15 as our top candidate. Genomic DNA sequencing of the two exons comprising SOX15 for the 20 PDAC lines did not reveal any mutations, suggesting DNA deletions and hypermethylation are the primary mechanisms of SOX15 inactivation in PDAC. 
SOX15 is ubiquitously underexpressed in PDAC lines
To validate the ubiquitous loss of SOX15 expression observed in PDAC lines, we performed qRT-PCR to measure SOX15 transcript levels in each line relative to HPDE. Confirming our microarray results, qRT-PCR revealed that SOX15 was underexpressed in all cell lines, with 15 of 20 lines having an expression level less than one percent of that observed in HPDE (Figure 2a ). Western blotting further corroborated our mRNA expression results, demonstrating a strong correlation between SOX15 mRNA and protein expression (Figure 2b ). We also observed significant underexpression of SOX15 in two distinct clinical PDAC cohorts (Figures 2c and d) . The reduced SOX15 expression levels observed in both cancer cell lines and clinical tumors suggests that underexpression is a consequence of the genomic alterations we observed, characteristic of TSG silencing.
SOX15 exhibits biological characteristics of a TSG in PDAC in vitro and in vivo Next, we ectopically expressed SOX15 in PDAC cell lines with undetectable SOX15 expression to assess its tumor suppressor capability. A full length SOX15 cDNA expression vector was introduced into Capan2 and Panc0327 to generate cells stably expressing SOX15 at levels comparable to those of non-malignant pancreatic cells (Figure 2b, Figures 3a and b) . Capan2-and Panc0327-SOX15 cells showed a reproducible and significant reduction in cell viability relative to Capan2-and Panc0327-EV (empty vector control) cells in vitro, as measured over 5 consecutive days using the MTT assay (Student's t-test, Po0.05, Figures 3c and d) . Given that SOX15 negatively affected cell viability in vitro, we then asked whether SOX15 could suppress growth in vivo. Capan2 and Panc0327 control cells, and cells stably expressing SOX15 were subcutaneously injected into the flank of severe combined immunodeficient mice and monitored for 7 weeks. All mice injected with empty vector cells (Capan2-EV and Panc0327-EV) developed tumors; however, Capan2-SOX15 and Panc03.27-SOX15 mice showed remarkably suppressed tumor formation (Figures 3e and f) , indicating SOX15 has a significant effect on impeding tumor formation.
SOX15 may exert its TSG effects via suppression of Wnt/b-catenin signaling After confirming its tumor suppressor abilities, we investigated the mechanism through which SOX15 mediates its TSG effects. Our pathway analysis suggested a role for SOX15 in the Wnt pathway based on the fact that other SOX proteins function as Wnt pathway antagonists, 14,40 thus, we assessed the effect of SOX15 expression on Wnt pathway activity using four different strategies. First, we quantified expression levels of six transcriptional targets of the Wnt pathway, AXIN2, CCND1, CD44, JUN, LEF1 and MYC in Capan2 cells with and without SOX15 expression. qRT-PCR confirmed our assumption that expression levels for these genes in Capan2-EV exceeded those in Capan2-SOX15 (Figure 4a ). The average fold change in expression for the Wnt target genes in Capan2-EV relative to Capan2-SOX15 ranged from 1.323-2.399 over three replicates. Second, we performed the TOP-Flash reporter assay, considered the gold standard for measuring Wnt pathway activity. After three independent replicates, the average fold change in Wnt activity in Capan2-EV relative to Capan2-SOX15 cells was 2.855 ( Figure 4b ). Third, we measured active b-catenin (unphosphorylated at serine 33 or threonine 37) levels. 31, 41 Corroborating our qRT-PCR and TOP-Flash results, active b-catenin levels were up to 18% lower in Capan2-SOX15 than in Capan2-EV (Figure 4c ). Lastly, we performed a gene set enrichment analysis on Capan2-EV and Capan2-SOX15 expression profiles (Supplementary Tables 6 and 7) to determine whether genes more highly expressed in Capan2-EV versus SOX15-expressing cells were enriched for TCF and LEF (members of the b-catenin complex) transcriptional targets. As hypothesized, C a p a n 1 C a p a n 2 C F P A C 1 H P A C H P A F I I H s 7 6 6 T P L 4 5 ACTB SOX15 45kDa 28kDa + c o n t r o l P a n c 0 2 . 0 3 P a n c 0 4 . 0 3 P a n c 1 0 . 0 5 P a n c 0 8 . 1 3 P a n c 0 5 . 2 4 P a n c 0 3 . 2 7 P a n c 1 M I A P a c a 2 S W 1 9 9 0 S U 8 6 8 6 C a p a n 1 C a p a n 2 C F P A C 1 H P A C H P A F I I H s 7 6 6 T P L 4 5 P a n c 0 2 . 0 3 P a n c 0 4 . 0 3 P a n c 1 0 . 0 5 P a n c 0 8 . 1 3 P a n c 0 5 . 0 4 P a n c 0 3 . 2 7 P a n c 1 M I A P a c a 2 S W 1 9 9 0 S U 8 6 8 6 P a n c 0 2 . 1 3 SOX15 inactivation in pancreatic cancer KL Thu et al LEF1, TCF1 and TCF4 transcriptional target gene sets were enriched in cells lacking SOX15 expression, which is consistent with elevated Wnt activity in Capan2-EV relative to Capan2-SOX15 (FDR qo0.05). These assays revealed a moderate but significant and repeatable decrease in Wnt activity in cells expressing SOX15 compared with isogenic cells lacking SOX15 expression, supporting an inhibitory role for SOX15 in Wnt signaling. Considering Capan2 has elevated Wnt activity to begin with and it also exhibits downregulation of other Wnt inhibitors (SFRP1 and DKK2, Figure 1c ), our observations of reduced Wnt activity when SOX15 is expressed is substantial. Although the specific mechanism of SOX15 involvement with Wnt-mediated transcription remains to be elucidated, our results provide evidence to support that SOX15 behaves as a TSG at least in part by repressing Wntdriven transcriptional activity in Capan2 cells.
Considering the profound effect of SOX15 overexpression on tumor growth in vivo and the moderate effect of SOX15 on Wnt activity, we investigated other avenues through which SOX15 may exert its tumor suppressor abilities using expression profiles for Capan2 cells with and without SOX15 expression. Pathway analysis of genes with two-fold expression changes (over or underexpressed) revealed ERK5 signaling as the top pathway affected, a pathway known to promote the hallmarks of cancer, including cell proliferation. 42, 43 The three genes identified in this pathway were FOS, MEF2C (downregulated when SOX15 is expressed) and MAP2K5 (namely MEK5, upregulated when SOX15 is expressed). Further exploration of the role of SOX15 in both the Wnt and ERK5 signaling pathways is warranted.
DISCUSSION
Whereas numerous approaches can be used for TSG identification, such as methylation profiling alone or mutation or homozygous deletion (HD) screening, we used a two-hit screening approach. We acknowledge that some TSGs may be haploinsufficient whereby mono-allelic disruption (that is inactivation by DNA alteration at only one allele) is enough to be functionally relevant. Nevertheless, we employed our integrative genomics strategy in which we simultaneously analyzed multiple dimensions of the cancer genome, and identified SOX15 as a candidate TSG in PDAC. Unlike other TSGs, such as RB1, p53 and p16, mutation is not the primary mechanism of SOX15 inactivation. Instead, we observed concurrent hypermethylation and DNA copy loss. We confirmed SOX15 inactivation in PDAC, and demonstrated its tumor suppressor abilities in cell and animal models. Our work demonstrates the power of a multi-dimensional genomics approach and its utility for the robust identification of novel cancer genes. A caveat of our study worth mentioning is that a single non-malignant cell line (HPDE) was used as a baseline for defining PDAC alterations, as opposed to a panel of nonmalignant pancreas lines. Despite this limitation, we were able to validate our findings in multiple publically accessible PDAC tumor studies where non-malignant pancreas tissues were used as controls, giving us confidence in the veracity of our data.
Members of the SOX family of transcription factors contain a high-mobility group box domain that facilitates DNA binding. They may act as transcriptional activators or repressors depending on their amino acid sequences and specific binding partners, and have emerged as important genes in a variety of tumor types. 14 SOX2 and SOX4 are oncogenes in lung and esophageal squamous cell carcinomas, and prostate and lung cancers, respectively, [44] [45] [46] whereas SOX6, SOX11 and SOX17 function as tumor suppressors in esophageal squamous cell carcinoma, hematopoietic malignancies, and gastric and liver cancers, respectively. 18, 20, 38, 39, 47 SOX15 exhibits classic features of a TSG. We observed frequent downregulation of SOX15 in two independent clinical pancreatic tumor cohorts in addition to our panel of cell lines, which suggests SOX15 inactivation is selected for in PDAC. Hypermethylation was observed in 80%, copy-number loss in 55% and underexpression in 100% of the 20 PDAC lines we profiled. Aberrant DNA methylation of SOX15 in pancreatic tumors has been reported, 16, 17 suggesting SOX15 methylation is not limited to cultured cells. Furthermore, Vincent et al. 16 demonstrated that DNA methylation contributes to SOX15 silencing, as treatment of PDAC cell lines with the DNA methyltransferase inhibitor 5-aza-2 0 -deoxycytidine reversed silencing of SOX15 expression.
The Catalog of Somatic Mutations in Cancer (COSMIC) database reports only one SOX15 mutation in cancer, which was found in the breast cancer cell line, HCC1395. 48 Although we and others did not detect sequence mutations in SOX15 in PDAC, deletions including HD of SOX15 are present in public genomic profiling data for pancreatic cancers illustrating another mechanism of SOX15 inactivation typically observed with other TSGs. 6 , 49 We did not observe any HDs of SOX15 in the PDAC cell lines, suggesting concurrent hypermethylation, and single copy loss is the primary mechanism of SOX15 disruption. Of interest, evaluation of public databases revealed that putative SOX15 HDs also occur in colon and prostate cancers and sarcomas. 50 Furthermore, querying the public data sets in The Cancer Genome Atlas data portal revealed four colon adenocarcinomas with concomitant copy-number loss, DNA methylation and low SOX15 expression, highlighting the TSG potential of SOX15 in colon cancer. Two cell lines in our study (HPAFII and SW1990) exhibited SOX15 underexpression in the absence of mutation, deletion or methylation, suggesting that additional unidentified mechanisms capable of silencing SOX15 exist.
In addition to genomic evidence for SOX15 as a TSG, we demonstrated the tumor suppressor potential of SOX15 in vitro and in vivo. Forced expression of SOX15 led to reduced cell viability in culture, and drastically reduced tumor formation in mice. These results strongly exemplify the tumor suppressor capacity of SOX15. Stable knockdown of SOX15 in HPDE did not cause a change in cell viability (data not shown), which is not surprising, given that a single molecular change alone is unlikely to transform non-malignant cells. Similar to our findings, overexpression of SOX15 in testicular embryonal carcinoma cells caused a reduction in cell proliferation further demonstrating the growth suppressive effects of SOX15 in cancer. 51 Besides its established role in muscle development, [52] [53] [54] [55] [56] little is known about the function of SOX15, especially in cancer. Yan et al. 51 found that overexpression of SOX15 in embyronal testicular carcinoma cells caused an increase of cells in the G1/G0 phase, a decrease of cells in the G2/M phase, and resulted in reduced cell proliferation. In contrast, Meeson et al. 54 found that SOX15 knockdown in myogenic progenitor cells induced G0/G1 arrest and a decrease in cell proliferation. These studies suggest SOX15 may have a role in cell cycle control that is likely cell type dependent. As we demonstrated that SOX15 suppressed Wntmediated transcription, it is possible that SOX15 downregulation helps to drive transcription of pro-proliferative genes, resulting in increased cell proliferation in PDAC cells.
Wnt pathway activation is a prominent feature of PDAC. 5, 6, 14, [25] [26] [27] 40 Genetic alterations promoting Wnt signaling in cancer include activating CTNNB1 (b-catenin) mutations, and inactivating AXIN and APC mutations. [57] [58] [59] These mutations are not often observed in PDACs and none have been reported in the cell line panel we studied, suggesting that other mechanisms exist to drive Wnt pathway activation. 6, 48, 57 Epigenetic silencing of DKK and SFRP genes, which encode inhibitors of receptor-ligand binding at the top of the Wnt signaling cascade, is another mechanism known to drive Wnt signaling in cancer. [28] [29] [30] [31] [32] [33] [34] 60 Additionally, a number of SOX family proteins (for example, SOX6, SOX9, SOX17) are known antagonists of the Wnt pathway. 14, 40 This prompted us to investigate a role for SOX15 in modulating Wnt/bcatenin signaling. We showed SOX15 expression had a modest but reproducible effect on suppressing Wnt activity in PDAC cells. Considering PDACs also exhibit downregulation of Wnt inhibitors including DKK2 and SFRP1, which likely contribute to aberrant Wnt signaling, we were impressed to observe a decrease in Wnt activity with the introduction of SOX15. We propose SOX15 silencing contributes to activation of Wnt signaling and may act cooperatively with genetic and/or epigenetic disruption of other Wnt pathway components in PDAC cells. To our knowledge, our study is not only the first to describe SOX15 as a candidate TSG in cancer, but also the first to establish SOX15 as a regulator of Wnt/bcatenin signaling. In addition to identifying a role for SOX15 in modulating the Wnt pathway, we also provide evidence suggesting its involvement in ERK5 signaling, although this role requires experimental validation.
The discovery that Wnt signaling is a key pathway in multiple cancers, has made the development of therapeutic Wnt inhibitors a priority for several malignancies including colorectal, liver, lung and PDAC. 58, 59, 61, 62 However, as the Wnt pathway is disrupted through a variety of mechanisms at the top (receptor-ligand binding), middle (b-catenin stability) and bottom (b-catenin/TCF complex transcription) levels of the pathway, elucidation of the most efficient therapeutic intervention points remains a challenge. 59 Our study demonstrates yet another mechanism of Wnt pathway disruption, which occurs downstream in the pathway, akin to CTNNB1 mutations in other cancer types. [57] [58] [59] Thus, the high frequency of SOX15 disruption and consequential expression of Wnt target genes warrants consideration of therapeutics aimed at targeting the nuclear level (for example, b-catenin/TCF complex) of the Wnt pathway in PDAC. Given the complexity of Wnt signaling and the multitude of alterations contributing to aberrant Wnt stimulation, assessment of the association between SOX15 status and response to Wnt-targeted therapeutics is a topic for future study.
MATERIALS AND METHODS
Cell lines and culture
The 20 PDAC cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) ( Table 1 ). Cells were cultured according to ATCC instructions. HPDE cells were generated by Dr M-S Tsao (Princess Margaret Hospital, Canada) and cultured in keratinocyte serumfree media supplemented with epidermal growth factor and bovine pituitary extract (Invitrogen, Burlington, ON, USA). DNA and RNA were isolated using phenol-chloroform and Trizol extractions.
DNA methylation profiling HM27 Infinium arrays were used to measure DNA methylation (Illumina, San Diego, CA, USA). 63 Data were processed using Bead Studio and the methylation level for each CpG locus, termed the b-value was calculated, reflecting the methylated signal as a proportion of total signal (methylated and unmethylated) for each CpG site. b-value differences between each PDAC line and HPDE were calculated for every CpG probe, and the probes with b-value differences in the 95th percentile of all b-value differences were considered hypermethylated.
DNA copy number profiling
Copy number profiles were generated using tiling path arrays, and processed and normalized as previously described. 64, 65 Each profile was then segmented to define the copy number status for each region as gained, lost or neutral using the breakpoint algorithm, FACADE.
66
Gene expression profiling Expression profiles for PDAC and HPDE cell lines were generated using Agilent 4 Â 44K expression arrays (Agilent, Mississauga, ON, USA). Expression values were normalized by dividing the background subtracted median intensity value by the median array intensity for each array. Fold change in expression relative to HPDE was calculated for each probe in each PDAC line. Genes were classified as underexpressed if the fold change was less than twofold. To reduce the potential overestimation of underexpression calls due to poor probe performance, the bottom 2% of expression values for HPDE were removed.
Profiles for Capan2 cells engineered to express SOX15 and corresponding controls (see below) were generated on HT-12 v4 Beadchips in duplicate (Illumina). Data were robust spline normalized using BRB array tools, replicate arrays were averaged, and fold changes between Capan2-EV and Capan2-SOX15 cells were calculated for each probe. 67 A pre-ranked gene set enrichment analysis was performed on fold change data using the C 3 transcription factor target v2.5 gene set to determine whether TCF/ LEF (Wnt responsive) transcription factor target genes were affected by SOX15 expression.
SOX15 expression was assessed in two publically available clinical cohorts. GSE11838 expression data was downloaded for 28 pancreatic tumors and four normal pancreas tissues using Agilent 60mer Oligo arrays. Data was normalized using median array normalization. GSE15471 downloaded data was comprised of Affymetrix U133 Plus expression arrays for 36 pancreatic tumor and 36 normal pancreas tissues. Array data was RMA normalized. Expression in tumors relative to normals was compared using a U test, with a P-valueo0.05 considered significant.
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Quantitative real-time PCR (qRT-PCR) SOX15 mRNA expression levels were quantified by quantitative real-time PCR (qRT-PCR) using TaqMan gene expression assays for SOX15 (Hs00199511_m1) and 18S (Hs99999901_s1) as an endogenous control (Life Technologies, Carlsbad, CA, USA). Relative expression levels were calculated using the DDCt method. Six Wnt target genes were also assessed using the following TaqMan primers: AXIN2 Hs00610344_m1, c-JUN Hs00277190_s1, c-MYC Hs00905030_m1, CD44 Hs01075861_m1, CCND1 Hs00765553_m1, LEF1 Hs01547250_m1.
SOX15 mutation screening
The two SOX15 exons were sequenced from genomic DNA for the 20 PDAC lines by the Sanger's method using primer pairs: exon 1-1 ( 0 , 5 0 -TTAGAGGTGGGTTAGGGGCA-3 0 ), cloned using the pENTR Directional TOPO Cloning Kit (Invitrogen, Carlsbad, CA, USA) and clones were verified by Sanger sequencing. The lentiviral SOX15 expression construct was generated using LR Recombinase Mix (Invitrogen) between pENTR and the destination vector, pLD_puro_CcF, 68 which contains a puromycin selective marker. Positive pLD_puro_SOX15 clones were sequence verified.
293T cells were co-transfected with pLD_puro_SOX15 or pLD_puro_CcF vectors and three packaging plasmids using Fugene transfection reagent 69 (Promega, Madison, WI, USA).A total of 3 ml of virus was used to infect 200 000 Capan2 cells. Puromycin (0.5 mg/ml) was added to the infected plates 48 h post infection. Capan2-SOX15 and Capan2-EV (pLD_puro_CcF empty vector control) cells were selected for two weeks. SOX15 expression was confirmed by qRT-PCR and western blotting.
PLKO vectors containing short-hairpin RNA targeting SOX15 were purchased from Open Biosystems (Waltham, MA, USA) (catalog RHS4533-NM_006942). Individual lentiviruses were prepared in 293T cells cotransfected with one of the four PLKO plasmids coding a SOX15 shorthairpin RNA and the viral packaging plasmids VSVG and d8.91 using TransIT-LT1 transfection reagent (Mirus, Madison, WI, USA). Virus containing empty PLKO vector served as a control. HPDE cells were infected with 2 ml of virus and selected with puromycin at 0.8 mg/ml, producing stable HPDE-PLKO and HPDE-shSOX15 cells. RNA was extracted from each line and the short-hairpin RNA producing the greatest SOX15 knockdown was used to assess cell viability. SOX15 expression was confirmed by qRT-PCR and western blotting.
Western blotting
Protein lysates were collected and western blots were performed as previously described. 70 SOX15 was assessed using a polycloncal sheep anti-human antibody (AF4070, R&D Systems, Minneapolis, MN, USA). Active b-catenin was measured with a mouse monoclonal antibody specific for dephosphorylated (at residues Ser37 or Thr41) b-catenin (#05-665, Millipore, Billerica, MA, USA). 31, 41 ACTB and GAPDH (#3700 and #2118, Cell Signaling, Danvers, MA, USA) were used as loading controls. Secondary antibodies included: antisheep (HAF016, R&D Systems), antirabbit and antimouse (#7074 and #7076, Cell Signaling). Band intensities were quantified using Adobe Photoshop CS4 (Adobe Systems, San Jose, CA, USA).
Cell viability assays
MTT assays were used to assess cell viability in stable Capan2-SOX15 and Capan2-EV cells as previously described. 71 Briefly, 3000 cells were seeded in triplicate in 96-well plates and viability was assessed for 5 consecutive days by the addition of MTT reagent (Invitrogen), followed by lysis with 20% SDS and quantification of absorbance with a spectrophotometer. Experiments were repeated twice.
In vivo mouse models
To assess the effect of SOX15 expression on tumor formation in vivo, Capan2-SOX15 and Capan2-EV cells were introduced into 4-6 week old male severe combined immunodeficient mice bred at the Ontario Cancer Institute animal facility. All manipulations were conducted in accordance with protocols approved by the OCI Animal Care Committee. Subcutaneous flank injections of two million cells in 50 ml of growth media were performed as previously described. 72 After 10 days, tumor size was measured by palpation through the skin every 3-4 days and tumor volume calculated (length Â width 2 Â p/6). Experiments were terminated after tumors reached 1.0-1.5 cm 3 . Differences in tumor burden were compared between mice injected with cell lines expressing SOX15 (n ¼ 5) and those expressing an empty vector (EV) (n ¼ 5) using a Student's t-test. Tumors formed were excised to confirm PDAC histology.
Wnt-activity reporter assays
Capan2-SOX15 and Capan2-EV cells were transfected with pTOPFlash or pFOPFlash plasmids containing multimerized wild-type and mutated TCF/LEF binding sites, respectively (Addgene plasmids 12456 and 12457, Cambridge, MA, USA). A Renilla reniformis luciferase reporter was used as an internal control for normalization of transfection efficiencies. Transfections were performed with Lipofectamine LTX (Invitrogen). Luciferase activities were measured 24 h post transfection using a luciferase reporter kit (E1910, Promega). Transfections were performed in triplicate and the fold change in luciferase activity of pTOPFlash to pFOPFlash was determined for each cell line. Experiments were repeated three times.
DNA methylation, copy number, and gene expression profiles for PDAC and HPDE lines have been deposited in the Gene Expression Omnibus (GSE40099). Supplementary Information including detailed methods accompany the paper on the Oncogene website (http://www.nature. com/onc).
